RBOT earnings analysis
What we found in RBOT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Vicarious Surgical Inc. reported a net loss of $7,329 for Q1 2026, significantly improved from $15,394 in Q1 2025. However, the company continues to show no revenue generation amidst ongoing operational challenges. The reduction in net loss highlights cost management, primarily from significant decreases in selling, general, and administrative expenses due to reduced headcount.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Reduction in Net Loss
- Net losses decreased from $15,394 in Q1 2025 to $7,329 in Q1 2026.
- Cost Reductions in Expenses
- S&M expenses decreased by 67% to $343, while G&A expenses dropped 60% to $2,120 in Q1 2026.
- Cash Position Holding Steady
- Cash and cash equivalents stood at $1,407, with total short-term investments of $2,275 by March 31, 2026.
- Operational Cash Flow Improvement
- Net cash used in operating activities improved from $11,768 in Q1 2025 to $6,325 in Q1 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Going Concern Doubts
- Management expressed substantial doubt about the company’s ability to continue as a going concern due to insufficient cash to support operations for the next 12 months.
- NYSE Delisting Risks
- The company was delisted from NYSE and is now trading on OTCID, which poses liquidity risks for shareholders.
- Material Weakness in Internal Controls
- The company has identified material weaknesses in its internal controls over financial reporting, which have not been remediated.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 9, 2026
- Vicarious Surgical remains a development-stage robotics company with no product revenue and continuing losses while it advances the single‑port Vicarious Surgical System toward FDA authorization. The filing emphasizes a…
- 10-Q · August 12, 2025
- Vicarious Surgical reported no revenue and a Q2 2025 net loss of $13,215 (EPS $(2.23)), an improvement versus Q2 2024 net loss of $15,205 (EPS $(2.59)). Total operating expenses declined to $13,519 in Q2 2025 from…
- 10-Q · May 12, 2025
- Vicarious Surgical reported a Q1 2025 net loss of $15,394 (EPS $(2.60)), an improvement from a $17,001 loss (EPS $(2.90)) in Q1 2024, while still reporting no revenue. Cash and short-term investments totaled $37,362 at…
- 10-K · March 17, 2025
- Vicarious Surgical remains a development-stage medical robotics company: it has not generated any product revenue and continues to incur operating losses while advancing its single‑port Vicarious Surgical System toward…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RBOT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever